中医药调控NLRP3炎性小体治疗脓毒症的研究进展

doi:10.3760/cma.j.issn.1007-1245.2022.01.007

国际医药卫生导报 ›› 2022, Vol. 28 ›› Issue (1): 28-32.DOI: 10.3760/cma.j.issn.1007-1245.2022.01.007

中医药调控NLRP3炎性小体治疗脓毒症的研究进展

林桦¹, 骆宁², 秦超², 于泳浩²

¹天津医科大学总医院空港医院麻醉科，天津　300300； ²天津医科大学总医院麻醉科天津市麻醉学研究所，天津　300052

收稿日期:2021-09-14 出版日期:2022-01-01 发布日期:2022-02-01
通讯作者: 于泳浩,Emai：yuyonghao@126.com
基金资助:
天津市卫生健康委员会科技项目（KJ2016）

Research progress of traditional Chinese medicine regulation of NLRP3 inflammasome in treatment of sepsis

Lin Hua¹, Luo Ning², Qin Chao², Yu Yonghao²

¹Department of Anesthesiology, Airport Site, General Hospital of Tianjin Medical University, Tianjin 300300, China; ²Department of Anesthesiology, General Hospital of Tianjin Medical University, Tianjin Institute of Anesthesiology, Tianjin 300052, China

Received:2021-09-14 Online:2022-01-01 Published:2022-02-01
Contact: Yu Yonghao,Emai：yuyonghao@126.com
Supported by:
Project of Science and Technology of Tianjin Health Commission (KJ2016)

摘要/Abstract

摘要： 脓毒症（sepsis）是目前最普遍的感染性疾病之一，炎性反应是脓毒症由轻度转化为脓毒症休克的重要机制。NOD样受体蛋白3（NOD-like receptor protein 3，NLRP3）炎性小体是人体内的一种蛋白复合物，受多种因素调控，可触发机体的免疫反应与细胞焦亡。当体内NLRP3炎性小体调控机制失衡，过度的炎性反应会引起细胞损伤，甚至形成不可逆的组织病变，并可加快器官损伤。目前，NLRP3炎性小体已作为脓毒症的潜在治疗靶点引起广泛关注。本文综述了NLRP3炎性小体主要的激活途径、NLRP3炎性小体影响脓毒症进程的机制及中医药在脓毒症中对NLRP3炎性小体的调控作用国内外研究进展。

关键词: NLRP3炎性小体, 脓毒症, 负调控, 炎性反应

Abstract: Sepsis is one of the most common infectious diseases. Inflammatory response is an important mechanism of sepsis from mild to septic shock. NOD like receptor protein 3 (NLRP3) inflammasome is a protein complex in human body. It is regulated by many factors and can trigger immune response and cell death. When the regulatory mechanism of NLRP3 inflammatory body is unbalanced, excessive inflammatory response will cause cell damage, even irreversible tissue lesions, and accelerate organ damage. At present, NLRP3 inflammasome has attracted extensive attention as a potential therapeutic target for sepsis. This paper reviews the main activation pathways of NLRP3 inflammasome, the mechanism of NLRP3 inflammasome affecting the process of sepsis, and the regulatory effect of traditional Chinese medicine on NLRP3 inflammasome in sepsis.

Key words: NLRP3 inflammasome, Sepsis, Negative regulation, Inflammatory reaction

林桦, 骆宁, 秦超, 于泳浩. 中医药调控NLRP3炎性小体治疗脓毒症的研究进展[J]. 国际医药卫生导报, 2022, 28(1): 28-32.

Lin Hua, Luo Ning, Qin Chao, Yu Yonghao. Research progress of traditional Chinese medicine regulation of NLRP3 inflammasome in treatment of sepsis[J]. International Medicine and Health Guidance News, 2022, 28(1): 28-32.

参考文献

[1] Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis [J]. N Engl J Med, 2015, 372(17):1629-1638. DOI: 10.1056/NEJMoa1415236.

[2] 陈泳祥,梁俊文,严建威. 脓毒症患者外周血单核细胞NLRP3炎性小体的表达研究[J]. 临床急诊杂志,2019,20(4):292-297. DOI:10.13201/j.issn.1009-5918.2019. 04.008.

[3] 韩浩贤,王虹艳,董昕. NLRP3炎症小体的研究现状[J]. 现代医药卫生,2015,31(19):2934-2936. DOI:10.3969/j.issn.1009-5519.2015.19.016.

[4] 李冬冬,周敏杰,朱晓光,等. NLRP3炎症小体调节创伤后炎症反应的作用[J]. 海南医学,2017,28(9):1455-1457. DOI:10.3969/j.issn.1003-6350.2017.09.028.

[5] 刘蓓桦,候梁,罗伟珏,等. LPS与ATP共同诱导巨噬细胞中NLRP3炎症小体的激活[J]. 北京农学院学报,2018,33(1):74-78. DOI:10.13473/j.cnki.issn.1002-3186.2018.0119.

[6] 陈淑珍. 内质网应激调控NLRP3炎症小体的研究进展[J]. 免疫学杂志,2017,33(10):905-910. DOI:10.13431/j.cnki.immunol.j.20170159.

[7] 丁杨,胡容. NLRP3炎症小体激活及调节机制的研究进展[J]. 药学进展,2018,42(4):294-302.

[8] NAN SONG,ZHAO-SHAN LIU,WEN XUE,等. NLRP3磷酸化是炎症小体激活的一个关键分子事件[J]. 科学新闻,2018(4): 88.

[9] Zhu H, Jian Z, Zhong Y, et al. Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition [J]. Front Immunol, 2021, 12: 714943. DOI: 10. 3389/fimmu.2021.714943.

[10] Chen Q, Wang Y, Jiao F, et al. HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway [J]. J Cell Mol Med, 2021, 25(15): 7218-7228. DOI: 10.1111/jcmm.16751.

[11] Huang Z, Zhou X, Zhang X, et al. Pien-Tze-Huang, a Chinese patent formula, attenuates NLRP3 inflammasome-related neuroinflammation by enhancing autophagy via the AMPK/mTOR/ULK1 signaling pathway [J]. Biomed Pharmacother, 2021, 141: 111814. DOI: 10.1016/j.biopha.2021.111814.

[12] Csak T, Ganz M, Pespisa J, et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells [J]. Hepatology, 2011, 54(1): 133-144. DOI: 10.1002/hep. 24341.

[13] Huang CH, Wang SC, Chen IC, et al. Protective effect of piplartine against LPS-induced sepsis through attenuating the MAPKs/NF-κB signaling pathway and NLRP3 inflammasome activation [J]. Pharmaceuticals (Basel), 2021, 14(6): 588. DOI: 10.3390/ph14060588.

[14] Biasizzo M, Trstenjak-Prebanda M, Dolinar K, et al. Cystatin C deficiency increases LPS-induced sepsis and NLRP3 inflammasome activation in mice [J]. Cells, 2021, 10(8): 2071. DOI: 10.3390/cells10082071.

[15] Qiu J, Xiao X, Gao X, et al. Ulinastatin protects against sepsisinduced myocardial injury by inhibiting NLRP3 inflammasome activation [J]. Mol Med Rep, 202, 24(4): 730. DOI: 10.3892/mmr.2021.12369.

[16] 黄钟,孙洁,姚振滨,等. TXNIP/NLRP3在脓毒症所致ALI/ARDS患者外周血中的表达[J]. 现代免疫学,2021,41(4):307-312.

[17] Shi X, Tan S, Tan S. NLRP3 inflammasome in sepsis (review) [J]. Mol Med Rep, 2021, 24(1): 514. DOI: 10.3892/mmr.2021.12153.

[18] Guo H, Ni M, Xu J, et al. Transcriptional enhancement of GBP-5 by BATF aggravates sepsis-associated liver injury via NLRP3 inflammasome activation [J]. FASEB J, 2021, 35(6): e21672. DOI: 10.1096/fj.202100234R.

[19] Jennings-Almeida B, Castelpoggi JP, Ramos-Junior ES, et al. Dietary fiber drives IL-1β-dependent peritonitis induced by Bacteroides fragilis via activation of the NLRP3 inflammasome [J]. J Immunol, 2021, 206(10): 2441-2452. DOI: 10.4049/jimmunol.2000078.

[20] 陈腾飞,陈剑明,徐霄龙,等. 中医古代脓毒症医案的疾病分布研究[J]. 中国中医急症,2021,30(8):1321-1323,1369. DOI:10.3969/j.issn.1004-745X.2021.08.002.

[21] 胡冠宇,胡亚坤,胡伊人,等. 中医药对脓毒症免疫调节的研究进展[J]. 中国中医急症,2019,28(5):930-933. DOI:10.3969/j.issn.1004-745X.2019.05.050.

[22] 高翠翠,鲁召新. 中医药在脓毒症治疗中的应用[J]. 中国中医急症,2010,19(4):648,658. DOI:10.3969/j.issn.1004- 745X.2010.04.059.

[23] 梁新,郭悦鹏. 茎叶人参皂苷对脓毒血症大鼠肺的保护作用[J]. 临床肺科杂志,2015, 20(4): 641-643. DOI:10.3969/j.issn.1009-6663.2015.04.019.

[24] Lan KC, Chao SC, Wu HY, et al. Salidroside ameliorates sepsis-induced acute lung injury and mortality via downregulating NF-κB and HMGB1 pathways through the upregulation of SIRT1 [J]. Sci Rep, 2017, 7(1):12026. DOI: 10.1038/s41598-017-12285-8.

[25] Lee YM, Cheng PY, Chim LS, et al. Baicalein, an active component of Scutellaria baicalensis Georgi, improves cardiac contractile function in endotoxaemic rats via induction of heme oxygenase-1 and suppression of inflammatory responses [J]. J Ethnopharmacol, 2011, 135(1):179-185. DOI: 10.1016/j.jep.2011.03.009.

[26] 李庆华,任永强,祖红旭,等. 乌司他丁联合黄连素对烧伤脓毒症的疗效分析[J]. 中国病理生理杂志,2016,32(12):2272-2275. DOI:10.3969/j.issn.1000-4718.2016.12.025.

[27] 武晓灵,喻莉,龙鼎,等. 盐酸小檗碱对脓毒症诱导急性呼吸窘迫综合征小鼠的保护作用及机制研究[J]. 实用医学杂志,2019,35(22):3452-3456. DOI:10.3969/j.issn.1006-5725. 2019.22.006.

[28] 王秀玉,张鸣号,邵群慧,等. 氧化苦参碱对脓毒症大鼠心肌细胞凋亡的影响[J]. 宁夏医学杂志,2014,36(4):294-296. DOI:10.13621/j.1001-5949.2014.04.0294.

[29] 胡星星,倪海滨,刘克琴,等. 大承气汤对脓毒症小鼠肺血管通透性影响[J]. 中国中医急症,2016,25(1):89-91. DOI:10.3969/j.issn.1004-745X.2016.01.029.

[30] 张慧妍,朱文献,苏文利,等. 大承气汤对脓毒症大鼠髓系细胞触发受体-1表达的影响[J]. 中国中西医结合急救杂志,2014(4):285-288. DOI:10.3969/j.issn.1008-9691.2014. 04.012.

[31] 朱耀文,张杰. 四逆汤合五苓散联合常规疗法治疗脓毒症致急性肾损伤30例临床观察[J]. 世界临床药物,2019,40(4):271-276. DOI:10.13683/j.wph.2019.04.009.

[32] 吴玉生,张道杰,李建军,等. 解毒化瘀方对脓毒症大鼠蛋白C mRNA表达及血浆蛋白C活性的影响[J]. 山东大学学报(医学版),2008,46(4):382-384,388.

[33] 钟世杰,黄华经,奚小土,等. 清气凉营汤对脓毒症的干预作用研究[J]. 中国中医急症,2009,18(1):29-30. DOI:10.3969/j.issn.1004-745X.2009.01.016.

[34] 王鸣,舒志军,张胜华,等. 栀子金花汤对腹腔感染脓毒症大鼠炎症介质的影响[J]. 中国中西医结合急救杂志,2007,14(3):169-172. DOI:10.3321/j.issn:1008-9691.2007. 03.012.

中医药调控NLRP3炎性小体治疗脓毒症的研究进展

Research progress of traditional Chinese medicine regulation of NLRP3 inflammasome in treatment of sepsis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics